CalAmp Corp. (NASDAQ:CAMP) trimmed its revenue outlook for the quarter. CalAmp shares fell 7.7% to $17.75 after hours. The company forecast revenue of about $71 million, down from a previous estimate of $73 million to $78 million, for the fourth quarter, and $86 million to $94 million for the first quarter. The first-quarter estimate includes 10 weeks of revenue from LoJack Corp., which the company acquired, CalAmp said.
CalAmp Corp. (NASDAQ:CAMP) shares moved down -8.27% in last trading session and ended the day at $17.64. CAMP Gross Margin is 35.80% and its has a return on assets of 5.50%. CalAmp Corp. (NASDAQ:CAMP) quarterly performance is -6.86%.
On 22 March, Spherix Incorporated (NASDAQ:SPEX) shares moved down -4.15% and was closed at $1.85. Spherix Incorporated (NASDAQ:SPEX) year to date (YTD) performance is -35.09%.
American Airlines Group Inc. (NASDAQ:AAL) announces all airport employees & crew members are safe, explosions did not occur where check-in operates in row 8 of departure hall, flight 751 from Brussels to Philadelphia cancelled.
American Airlines Group Inc. (NASDAQ:AAL) ended the last trading day at $42.76. Company weekly volatility is calculated as 2.29% and price to cash ratio as 2.91. American Airlines Group Inc. (NASDAQ:AAL) showed a weekly performance of 1.54%.
On March 15, Spherix Incorporated (NASDAQ:SPEX) announced that the Company had executed an additional agreement to monetize the Nortel patents with Equitable IP Corporation (“Equitable”), a leading patent enforcement and monetization fund.
Anacor Pharmaceuticals, Inc. (NASDAQ:ANAC) announces that the FDA has accepted for review the NDA for crisaborole topical ointment 2% for the treatment of mild-to-moderate atopic dermatitis in children and adults. The co announced that the U.S. Food and Drug Administration has accepted for review Anacor’s New Drug Application (:NDA) seeking approval of crisaborole topical ointment, 2%, a novel non-steroidal topical anti-inflammatory phosphodiesterase-4 (PDE-4) inhibitor in development for the potential treatment of mild-to-moderate atopic dermatitis in children and adults. The Prescription Drug User Fee Act goal date for the completion of the FDA’s review is January 7, 2017.
Anacor Pharmaceuticals, Inc. (NASDAQ:ANAC) caters to the Healthcare space. It has a net profit margin of -74.40% and weekly performance is -3.57%. On the last day of trading company shares ended up at $59.99. Anacor Pharmaceuticals, Inc. (NASDAQ:ANAC) distance from 50-day simple moving average (SMA50) is 2.98%.
Microvision Inc. (NASDAQ:MVIS) announced the pricing of an underwritten public offering of 3,529,412 shares of its common stock at a public offering price of $1.70 per share, for gross proceeds of approximately $6.0 million. MicroVision also granted the underwriter a 30-day option to purchase up to an additional 529,411 shares of common stock to cover over-allotments, if any.
Microvision Inc. (NASDAQ:MVIS) shares advanced 5.11% in last trading session and ended the day at $1.85. MVIS Gross Margin is 21.70% and its has a return on assets of -83.10%. Microvision Inc. (NASDAQ:MVIS) quarterly performance is -32.73%.